Literature DB >> 33451264

The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study.

Alessandro Bisio1, Linda Gonder-Frederick1,2, Ryan McFadden1, Daniel Cherñavvsky1, Mary Voelmle1,3, Michael Pajewski1, Pearl Yu4, Heather Bonner4, Sue A Brown1,3.   

Abstract

BACKGROUND: Older adults with type 1 diabetes (≥65 years) are often under-represented in clinical trials of automated insulin delivery (AID) systems. We sought to test the efficacy of a recently FDA-approved AID system in this population.
METHODS: Participants with type 1 diabetes used sensor-augmented pump (SAP) therapy for four weeks and then used an AID system (Control-IQ) for four weeks. In addition to glucose control variables, patient-reported outcomes (PRO) were assessed with questionnaires and sleep parameters were assessed by actigraphy.
RESULTS: Fifteen older adults (mean age 68.7 ± 3.3, HbA1c of 7.0 ± 0.8) completed the pilot trial. Glycemic outcomes improved during AID compared to SAP. During AID use, mean glucose was 146.0 mg/dL; mean percent time in range (TIR, 70-180 mg/dL) was 79.6%; median time below 70 mg/dL was 1.1%. The AID system was in use 92.6% ± 7.0% of the time. Compared to SAP, while participants were on AID the TIR increased significantly (+10%, P = .002) accompanied by a reduction in both time above 180 mg/dL (-6.9%, P = .005) and below 70 mg/dl (-0.4%, P = .053). Diabetes-related distress decreased significantly while using AID (P = .028), but sleep parameters remained unchanged.
CONCLUSIONS: Use of this AID system in older adults improved glycemic control with high scores in ease of use, trust, and usability. Participants reported an improvement in diabetes distress with AID use. There were no significant changes in sleep.

Entities:  

Keywords:  artificial pancreas; automated insulin delivery; closed-loop control; continuous glucose monitoring; continuous subcutaneous insulin infusion; sensor-augmented pump therapy

Mesh:

Substances:

Year:  2021        PMID: 33451264      PMCID: PMC9294584          DOI: 10.1177/1932296820986879

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  28 in total

1.  Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.

Authors:  Sue A Brown; Boris P Kovatchev; Dan Raghinaru; John W Lum; Bruce A Buckingham; Yogish C Kudva; Lori M Laffel; Carol J Levy; Jordan E Pinsker; R Paul Wadwa; Eyal Dassau; Francis J Doyle; Stacey M Anderson; Mei Mei Church; Vikash Dadlani; Laya Ekhlaspour; Gregory P Forlenza; Elvira Isganaitis; David W Lam; Craig Kollman; Roy W Beck
Journal:  N Engl J Med       Date:  2019-10-16       Impact factor: 91.245

2.  National Sleep Foundation's sleep quality recommendations: first report.

Authors:  Maurice Ohayon; Emerson M Wickwire; Max Hirshkowitz; Steven M Albert; Alon Avidan; Frank J Daly; Yves Dauvilliers; Raffaele Ferri; Constance Fung; David Gozal; Nancy Hazen; Andrew Krystal; Kenneth Lichstein; Monica Mallampalli; Giuseppe Plazzi; Robert Rawding; Frank A Scheer; Virend Somers; Michael V Vitiello
Journal:  Sleep Health       Date:  2016-12-23

3.  Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.

Authors:  Pierre-Yves Benhamou; Sylvia Franc; Yves Reznik; Charles Thivolet; Pauline Schaepelynck; Eric Renard; Bruno Guerci; Lucy Chaillous; Celine Lukas-Croisier; Nathalie Jeandidier; Helene Hanaire; Sophie Borot; Maeva Doron; Pierre Jallon; Ilham Xhaard; Vincent Melki; Laurent Meyer; Brigitte Delemer; Marie Guillouche; Laurene Schoumacker-Ley; Anne Farret; Denis Raccah; Sandrine Lablanche; Michael Joubert; Alfred Penfornis; Guillaume Charpentier
Journal:  Lancet Digit Health       Date:  2019-05-02

4.  Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey.

Authors:  Meryl Brod; Torsten Christensen; Donald M Bushnell
Journal:  J Med Econ       Date:  2011-10-27       Impact factor: 2.448

5.  Melatonin synthesis impairment as a new deleterious outcome of diabetes-derived hyperglycemia.

Authors:  Fernanda G Amaral; Ariane O Turati; Mark Barone; Julieta H Scialfa; Daniella do Carmo Buonfiglio; Rafael Peres; Rodrigo A Peliciari-Garcia; Solange C Afeche; Larissa Lima; Cristoforo Scavone; Silvana Bordin; Russel J Reiter; Luiz Menna-Barreto; José Cipolla-Neto
Journal:  J Pineal Res       Date:  2014-06-03       Impact factor: 13.007

6.  Partial sleep restriction decreases insulin sensitivity in type 1 diabetes.

Authors:  Esther Donga; Marieke van Dijk; J Gert van Dijk; Nienke R Biermasz; Gert-Jan Lammers; Klaas van Kralingen; Roel P L M Hoogma; Eleonora P M Corssmit; Johannes A Romijn
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

7.  National Sleep Foundation's updated sleep duration recommendations: final report.

Authors:  Max Hirshkowitz; Kaitlyn Whiton; Steven M Albert; Cathy Alessi; Oliviero Bruni; Lydia DonCarlos; Nancy Hazen; John Herman; Paula J Adams Hillard; Eliot S Katz; Leila Kheirandish-Gozal; David N Neubauer; Anne E O'Donnell; Maurice Ohayon; John Peever; Robert Rawding; Ramesh C Sachdeva; Belinda Setters; Michael V Vitiello; J Catesby Ware
Journal:  Sleep Health       Date:  2015-10-31

8.  Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being.

Authors:  Meryl Brod; Betsy Pohlman; Michael Wolden; Torsten Christensen
Journal:  Qual Life Res       Date:  2012-07-24       Impact factor: 4.147

9.  Older Adults Perceptions of Technology and Barriers to Interacting with Tablet Computers: A Focus Group Study.

Authors:  Eleftheria Vaportzis; Maria Giatsi Clausen; Alan J Gow
Journal:  Front Psychol       Date:  2017-10-04

Review 10.  International Consensus on Use of Continuous Glucose Monitoring.

Authors:  Thomas Danne; Revital Nimri; Tadej Battelino; Richard M Bergenstal; Kelly L Close; J Hans DeVries; Satish Garg; Lutz Heinemann; Irl Hirsch; Stephanie A Amiel; Roy Beck; Emanuele Bosi; Bruce Buckingham; Claudio Cobelli; Eyal Dassau; Francis J Doyle; Simon Heller; Roman Hovorka; Weiping Jia; Tim Jones; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; David Maahs; Helen R Murphy; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; Banshi Saboo; Mauro Scharf; William V Tamborlane; Stuart A Weinzimer; Moshe Phillip
Journal:  Diabetes Care       Date:  2017-12       Impact factor: 19.112

View more
  4 in total

1.  Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.

Authors:  Benjamin J Wheeler; Olivia J Collyns; Renee A Meier; Zara L Betts; Chris Frampton; Carla M Frewen; Barbara Galland; Niranjala M Hewapathirana; Shirley D Jones; Denis S H Chan; Anirban Roy; Benyamin Grosman; Natalie Kurtz; John Shin; Robert A Vigersky; Martin I de Bock
Journal:  Acta Diabetol       Date:  2021-08-27       Impact factor: 4.280

2.  Closed-Loop Insulin Therapy in Older Adults with Type 1 Diabetes: Real-World Data.

Authors:  Elena Toschi; Astrid Atakov-Castillo; Christine Slyne; Medha Munshi
Journal:  Diabetes Technol Ther       Date:  2021-10-28       Impact factor: 6.118

3.  Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.

Authors:  Charlotte K Boughton; Sara Hartnell; Hood Thabit; Womba M Mubita; Katharine Draxlbauer; Tina Poettler; Malgorzata E Wilinska; Korey K Hood; Julia K Mader; Parth Narendran; Lalantha Leelarathna; Mark L Evans; Roman Hovorka
Journal:  Lancet Healthy Longev       Date:  2022-03-07

4.  Review of Automated Insulin Delivery Systems for Individuals with Type 1 Diabetes: Tailored Solutions for Subpopulations.

Authors:  Eleonora M Aiello; Sunil Deshpande; Basak Ozaslan; Kelilah L Wolkowicz; Eyal Dassau; Jordan E Pinsker; Francis J Doyle
Journal:  Curr Opin Biomed Eng       Date:  2021-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.